<code id='DE2F005637'></code><style id='DE2F005637'></style>
    • <acronym id='DE2F005637'></acronym>
      <center id='DE2F005637'><center id='DE2F005637'><tfoot id='DE2F005637'></tfoot></center><abbr id='DE2F005637'><dir id='DE2F005637'><tfoot id='DE2F005637'></tfoot><noframes id='DE2F005637'>

    • <optgroup id='DE2F005637'><strike id='DE2F005637'><sup id='DE2F005637'></sup></strike><code id='DE2F005637'></code></optgroup>
        1. <b id='DE2F005637'><label id='DE2F005637'><select id='DE2F005637'><dt id='DE2F005637'><span id='DE2F005637'></span></dt></select></label></b><u id='DE2F005637'></u>
          <i id='DE2F005637'><strike id='DE2F005637'><tt id='DE2F005637'><pre id='DE2F005637'></pre></tt></strike></i>

          Home / explore / comprehensive

          comprehensive


          comprehensive

          author:knowledge    Page View:813

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In